Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Dacarbazine (DTIC) Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00110994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00110994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Dacarbazine (DTIC) Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
March 31, 2008
Enrollment
101 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, melanoma